Skip to main content
. 2021 Jan 21;12(5):667–675. doi: 10.1111/1759-7714.13792

Figure 3.

Figure 3

OS curve of patients with ILD associated with NSCLC who received chemotherapy according to the GPS (GPS 0, n = 31; GPS 1, n = 16; GPS 2, n = 9). GPS, Glasgow Prognostic Score; ILD, interstitial lung disease; NSCLC, non‐small cell lung cancer; OS, overall survival. Median OS (Inline graphic) GPS 0: 16.9 months (n = 31), (Inline graphic) GPS 1: 9.8 months (n = 16), and (Inline graphic) GPS 2: 7.6 months (n = 9).